Skip to content

In the BioHarmony Drug Report Database

Bexarotene

Targretin (bexarotene) is a small molecule pharmaceutical. Bexarotene was first approved as Targretin on 1999-12-29. It is used to treat t-cell lymphoma cutaneous in the USA. It has been approved in Europe to treat t-cell lymphoma cutaneous. The pharmaceutical is active against retinoic acid receptor RXR-gamma, retinoic acid receptor RXR-alpha, and retinoic acid receptor RXR-beta. In addition, it is known to target peroxisome proliferator-activated receptor gamma.
Trade Name Targretin
Common Name Bexarotene
Indication t-cell lymphoma cutaneous
Drug Class Arotinoid derivatives
Bexarotene
Get full access now